Lv1
40 积分 2024-01-06 加入
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
2小时前
待确认
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
5个月前
已完结
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
10个月前
已完结
皖公网安备34019202002308
